Coherus Oncology, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Coherus Oncology, Inc. (Nasdaq: CHRS) develops and commercializes immuno-oncology therapies for cancer patients, with a focus on next-generation combination treatments targeting the tumor microenvironment; its approved products include LOQTORZI (toripalimab-tpzi), an anti-PD-1 monoclonal antibody indicated for recurrent or metastatic nasopharyngeal carcinoma in combination with chemotherapy or as monotherapy; its pipeline features clinical-stage candidates such as casdozokitug, a first-in-class IL-27 antagonist evaluated in Phase 1/2 and Phase 2 trials for non-small cell lung cancer, hepatocellular carcinoma, and clear cell renal cell carcinoma; CHS-114, a cytolytic anti-CCR8 antibody in Phase 1 studies for advanced solid tumors including head and neck squamous cell carcinoma and gastric cancer; and CHS-1000, an anti-ILT4 antibody advancing toward first-in-human trials following FDA IND clearance in 2024. The company, founded in 2010 and headquartered in Redwood City, California, operates primarily in the United States with ongoing clinical trials across multiple solid tumor indications. In a strategic shift from biosimilars, Coherus completed the divestiture of its UDENYCA (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals in April 2025 for up to $558 million, following earlier sales of Cimerli and Humira biosimilars; it acquired Surface Oncology in September 2023, adding casdozokitug and CHS-114 to its portfolio; and continues to expand LOQTORZI through internal combinations with pipeline assets and planned external partnerships for label expansions in additional cancers.
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
Coherus Oncology: Setting Up For Important Readouts In Mid-2026
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
Coherus Oncology Q1 Earnings Call Highlights
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives $5.51 Consensus Target Price from Brokerages
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
Coherus Oncology to Participate in Upcoming Investor Conferences
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of “Hold” by Analysts
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200-Day Moving Average – What’s Next?
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript